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Hyperthermicisolated limb perfusion (HILP)is considered an established treatment for multiplelocoregional intransitmetastases
in malignant melanoma of the extremities. Various mechanisms such as the expression of chemoresistance genes and heat shock
proteins by the tumor may be responsible for varying response rates and locoregional recurrences of the treatment. The aim of
the experimental animal study was to investigate the direct impact of HILP on such mechanisms of resistance. Tissue temperature,
administrationofthecytostaticdrug,anddurationofperfusionwerevaried.Expressionofthechemoresistancegenesmdr1,mrp1,
mrp2, and lrp and of heat shock protein 72 (HSP72) in the tumor tissue was analysed using RT-PCR and western blot analysis.
The untreated SK-MEL-3 tumor expressed mdr1, mrp1, and lrp, but not mrp2. Neither variation of temperature, administration
of the cytostatic drug, nor duration of perfusion changed the expression of this “resistance pattern”. In contrast to the cytostatic
drug, hyperthermia causes a persistent induction of HSP72. Both observations could oﬀer a potential explanation for failure of
HILP in malignant melanoma.
1.Introduction
Hyperthermic isolated limb perfusion (HILP) is regarded as
an established therapy for locoregional intransit metastases
of malignant melanoma of the extremities. Isolation of
the limb by extracorporeal circulation, that is, by using a
heart-lung-machine, enables administration of high doses
of cytostatic drugs without relevant systemic side eﬀects.
Simultaneous heating of the limb up to temperatures of
40.0
◦Ct o4 1 .0
◦C intensiﬁes the tumortoxic action of the
drug [1]. Although HILP represents a form of regional high-
dose thermo-chemotherapy, partial response or treatment
failureisobservedin25–50%ofpatients.Furthermore,upto
50% of patients with previous complete remission following
HILP will undergo relapse on the treated limb, usually after
a median of 9–12 months [2–4].
Among the main causes for failure of treatment is the
resistance of tumor cells against the action of cytostatic
drugs, which is based on the expression of certain genes
such as the multidrug resistance gene (mdr1), coding for
the p-glycoprotein (p-gp)[ 5] .T h eg e n ep r o d u c tf u n c t i o n s
as an energy-dependent membrane-bound transport protein
for hydrophobic, cytotoxic agents such as anthracyclines,
epipodophyllotoxins, vinca alcaloids and taxol, thus low-
ering their intracellular concentration by drug eﬄux [6].
Meanwhile other chemoresistance-related proteins like the
multidrug resistance protein MRP1 and its isoform MRP2
(canalicular MRP, cMRP; canalicular multispeciﬁc organic
anion transporter, cMOAT) and the lung resistance-related
protein (LRP) have been identiﬁed [7, 8].
Furthermore, the expression of various heat shock pro-
teins (HSP) has been associated with resistance of tumor
cells to thermal and chemical damage [9]. The function
of the diﬀerent families of heat shock proteins is complex
and has not yet been understood in full detail. One of
the proteins highly inducible under stress conditions is
the 72kD heat shock protein (HSP72), a member of the
HSP70 family. According to their function as molecular2 Journal of Oncology
Table 1: Group I (n = 12). Gene expression by variation of
perfusiontimeatnormothermicconditionswithoutcytostaticdrug
(gene expression/number of tumor samples).
Untreated tumor Perfusion time (minutes)
30 60 90 60 + 5 hours
Gene
mdr1 3/3 3/3 3/3 3/3 3/3
mrp1 3/3 3/3 2/3 3/3 2/3
mrp2 0/3 0/3 0/3 0/3 0/3
lrp 3/3 3/3 3/3 3/3 3/3
chaperones [10], a cell-protective eﬀect is ascribed to these
proteins after impairment of normal cell physiology by toxic
stimuli such as heat, ischemia, and inﬂammation, although
meanwhile proapoptotic cascades have also been linked with
the induction of HSP [11]. Tumor cells respond to HSP-
mediated stress in the same way and can escape the action
of tumortoxic therapies.
This has prompted us to investigate the direct impact
of HILP on molecular mechanisms of resistance of malig-
nant melanoma in an experimental study. A set of well-
characterized chemoresistance-related genes (i.e., mdr1,
mrp1, mrp2, lrp) and HSP72 were selected for targets of the
eﬀects of HILP for purposes of the study.
2.MaterialsandMethods
2.1. Cell Lines and Animals. KB-3-1 cell-line (DSZM, Braun-
schweig,FRG):asaderivativeofthehumancervixcarcinoma
cell line HELA, it is used in multiple drug resistance
studies giving rise to drug-resistance mutants (e.g., KB-V1,
resistant to vinblastine). KB-3-1 is negative for mdr1 mRNA
expression and served as a negative control in the mdr1
detection experiments.
SK-MEL-3 cell-line (American Type Culture Collection,
Rockeville/Md., US): cell line established from a lymph
node metastasis of malignant melanoma in a 42-year-old
Caucasian woman. A cell suspension of SK-MEL-3 was
injected subcutaneously on athymic nude mice (NMRI
nu/nu) to create a solid tumor. Small particles (approx.
5mm 3) of the tumor were implanted subcutaneously on the
right hind limbs of the study animals by means of small skin
incision.
Animals: for experimental limb perfusions eight-week-
old athymic nude rats (Rowett rnu/rnu) weighing 200–250g
and bearing the SK-MEL-3 xenograft on their right hind
limbs were used. Perfusions were performed when the tumor
reached a size of approximately 25mm2.
2.2. Drug. 10mg of dry substance vinblastine sulfate (Velbe,
Lilly, Bad Homburg, FRG) were dissolved in 10ml 0.9%
NaCl. For experimental perfusions, 25μg vinblastine/15ml
priming volume were injected as a fractionated bolus over 2
minutes into the arterial line. Previous dose-ﬁnding studies
had shown that this concentration was well tolerated by
the animals and led to complete tumor regression in single
Table 2: Group II (n = 12). Gene expression by variation of
perfusion time at normothermic conditions with vinblastine (gene
expression/number of tumor samples).
Untreated tumor Perfusion time (minutes)
30 60 90 60 + 5 hours
Gene
mdr1 3/3 3/3 3/3 3/3 3/3
mrp1 3/3 3/3 3/3 1/3 2/3
mrp2 0/3 2/3 0/3 0/3 0/3
lrp 3/3 3/3 3/3 3/3 3/3
animals. Vinblastine was chosen because of its cytotoxic
eﬀect on melanoma cell lines, which has been proven in
former experimental perfusion studies [12]. Furthermore,
vinblastine is one of the substrates that is eliminated by the
p-glycoprotein pathway.
2.3. HILP Treatment and Surgery. A modiﬁed miniature
equipment, ﬁrst described by Nagel et al. 1987 [13], for rat
limb perfusion was used. Our technique of experimental
perfusion has been described in detail earlier [1].
In brief, after induction of anesthesia, the animal was
ﬁxed in a supine position on a cork-coated operation table.
A vertical skin incision was performed in the right groin
and the inguinal ligament was divided. The external iliac
and femoral vessels were exposed by retracting the peri-
toneal sac in craniomedial direction. After heparinization
with 1000IE/kg body weight, all collateral vessels were
temporarily clipped to reduce systemic leakage. After central
clamping of the external iliac artery and vein, both vessels
were cannulated under microscopic control (G 24 and G 20
catheters, resp.). The catheters were connected with the per-
fusion system and the extracorporeal circulation was started
with a ﬂow rate of 0.4ml/kg body weight. A subcutaneous
temperature probe (Yellow Springs Instrument Co., US) was
placed near the tumor for continuous registration of tissue
temperature (St¨ ockert, FRG).
The extracorporeal circulation was achieved using a
Masterﬂex roller pump (Reichelt, FRG) with two pump-
heads running synchronously on a single axis for the arterial
and venous line. Venous blood from the tumor bearing limb
was directed towards a specially constructed gas dispersion
oxygenator (Lettenbauer, FRG) made of high-quality acryl
with foam material taken from commercially available oxy-
genators. The oxygenated blood was then redirected into the
limb.Tygontubing(Reichelt,FRG)withaninternaldiameter
of 0.8mm was used for circulation of the perfusate. 3-way
taps in the arterial and venous line allowed injection of the
drug, measurement of blood gas analysis, and registration of
perfusion pressure (if necessary). Hyperthermia was induced
by an externally adjustable infrared light source centered
onto the tumor area.
2.4. Treatment Schedule. Apart from the analysis of the
untreated tumor (n = 3), four groups with 12 animals
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Figure 1: Group I (n = 12). HSP72 expression in normothermic
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Figure 2: Group II (n = 12). HSP72 expression in normothermic
limb perfusion with vinblastine.
perfusions (tissue temperature, 37–37.5
◦C) without vinblas-
tine, group II normothermic perfusions with vinblastine
(25μg/15 mL perfusate), group III hyperthermic perfu-
sions (tissue temperature 40.0-41.0
◦C) without vinblastine,
and group IV hyperthermic perfusions with vinblastine
(25μg/15mL perfusate). Each group (n = 12) was divided
into four subgroups (n = 3) with variation of perfusion
time. The duration of perfusion was 30, 60, and 90 minutes.
In the fourth subgroup, animals survived 5 hours after a
60-minute perfusion to evaluate early posttreatment eﬀects.
After the scheduled perfusion time, the tumor was excised
and instantly frozen in liquid nitrogen.
2.5. cDNA-Synthesis and Reverse Transcriptase-Polymerase
Chain Reaction (RT-PCR). Gene expression was monitored
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Figure 3: Group III (n = 9). HSP72 expression in hyperthermic
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Figure 4: Group IV (n = 9). HSP72 expression in hyperthermic
limb perfusion with vinblastine.
from 30mg tissue samples using the QIAGEN RNeasy-
kit. cDNA was synthesized with 1μg of total cellular RNA
and 50pmol of random hexanucleotide primer (Perkin
Elmer) in 20μl of a solution containing 5mM MgCl2,
1xPCR-buﬀer II (Perkin Elmer), 500μMe a c hd N T P ,2 0 U
Rnase Inhibitor (Perkin Elmer), and 50U MuLV Reverse
Transcriptase (Perkin Elmer). The reaction was performed
using a Trio-Thermoblock (Biometra) with the following
program: 21
◦C for 10 minutes, 42
◦C for 60 minutes, and
denaturation at 95
◦C for 5 minutes. Water was added to
aﬁ n a lv o l u m eo f5 0 μl and cDNA was stored at −20
◦C
before it was used. RT-PCR was performed with 5μlo f
cDNA template in a 50μl reaction containing 0.15mM
MgCl2,1 0m MT r i s / H C lp H8 ,3 ;5 0m MK C l ,5 0p m o l5  -
primer, 50pmol 3 -primer, 2.5U Ampli-Taq Gold (Perkin
Elmer). After denaturation at 95
◦C for 5 minutes, PCR
was performed as follows: 45 seconds 94
◦C, 45 seconds4 Journal of Oncology
Table 3: Group III (n = 9). Gene expression by variation of
perfusion time at hyperthermic conditions without cytostatic drug
(gene expression/number of tumor samples), n.d. = not done (see
text).
Untreated tumor Perfusion time (minutes)
30 60 90 60 + 5 hours
Gene
mdr1 3/3 3/3 3/3 n.d. 3/3
mrp1 3/3 3/3 1/3 n.d. 3/3
mrp2 0/3 2/3 0/3 n.d. 0/3
lrp 3/3 3/3 3/3 n.d. 3/3
60
◦C, 90 seconds 72
◦C for 34 cycles, with an additional
elongation step at 72
◦C for 3 minutes, PCR products were
analyzed on a 2.5% Agarose gel. PCR-primer sequences were
mdr1-51 5 -GTT.CAA.ACT.TCT.GCT.CCT.GAG-3 ; mdr1-
31 5 -ACC.CAT.CAT.TGC.AAT.AGC.AGG-3 ; mrp1-51 5 -
ACC.GGA.GGA.TGT.TGA. ACA.AG-3 ; mrp1-31 5 -AAT.
GCG.CCA.AGA.CTA.GGA.AG-3 ; mrp2-51 5 -CTG.CCA.
TAA.TGT. CCA.GGT.TC-3 ; mrp2-31 5 -CTG.GTT.GAT.
GAA.GGC.TCT.GT-3 ; lrp1-51 5 -TGG.AGC.CAT.CGG.
TGA.TGA.GG-3 ; lrp1-31 5 -TCT.GAG.CAT.GGC.CGT.
GGA.GA-3 .
The expression of GAPDH was used as a positive control
in each RT-PCR analysis (primer sequence: GAPDH-31
5 -CCA.TCA.CCA.TCT.TCC.AGG.AG-3 , GAPDH-51 5 -
CCT.GCT. TCA.CCA.CCT.TCT.TG-3 ).
2.6. Western Blot Analysis. HSP72 was monitored by western
blot analysis. In addition, the gene product of mdr1,
the p-glycoprotein, was measured representatively for all
chemoresistance genes by the western blot method to detect
the transcriptional activity of the gene. Total protein samples
were prepared from 50mg tissue samples, adding 100μlo f
Tris/HCl pH 7.5, 0.1% SDS, using a Micro-Dismembranator
for 60 seconds, 2000rpm. 500μl of 10mM Tris/HCl pH
7.5; 1.0% SDS was added to the cell suspension and
boiled for 10 minutes. After centrifugation for 10 minutes
at 13.000rpm, supernatant was collected and the protein
content was measured by BioRad-Protein-Assay. 25μgo f
protein was applied per lane to a 7.5% SDS-PAGE-gel for
MDR1 protein analysis and 12% SDS-PAGE gel for HSP72
analysis. The gel was blotted on a nitrocellulose membrane
with 0.8mA/cm2 gel for 1.5 hours using a semidry gel-
blotting apparatus. The membrane was blocked using a 5%
solution of blocking-reagent (Amersham) in TBS-T, for one
hour at room temperature. Protein detection was performed
with “Monoclonal Anti-72kDa heat shock protein” (Amer-
sham Life Science) and “mdr (P-glycoprotein) (Ab-1)” (Cal-
biochem). Incubation was performed at room temperature
for one hour. After three washing steps, secondary anti-
bodies, antimouse-Antibody (Amersham), and antirabbit-
antibody (Amersham), respectively, were applied. Antibody
detection was done with ECL-System (Amersham Life
Science).
Table 4: Group IV (n = 9). Gene expression by variation of
perfusion time at hyperthermic conditions with vinblastine (gene
expression/number of tumor samples), n.d. = not done (see text).
Untreated tumor Perfusion time (minutes)
30 60 90 60 + 5 hours
Gene
mdr1 3/3 3/3 3/3 n.d. 3/3
mrp1 3/3 3/3 3/3 n.d. 3/3
mrp2 0/3 1/3 1/3 n.d. 0/3
lrp 3/3 3/3 3/3 n.d. 3/3
2.7. Evaluation of HSP72 Expression. HSP72 expression was
evaluated semiquantitatively by densitometric measurement
and band analysis with the imaging software TINA (Raytest).
Bands were compared to a dilution series of protein samples
to calculate fold expression. Pixel areas of the bands in each
group (n = 3) were averaged and related to the mean pixel
area of the untreated tumor which represented the value 1.
3. Results
All experimental perfusions could be performed as planned
except the 90-minute hyperthermic perfusions (with and
without vinblastine) which were not tolerated by the study
animals (intraoperative exitus). Thus, the number of experi-
mental perfusions actually performed totalled 42.
3.1. Expression of Chemoresistance Genes. Mdr1,m r p 1 ,a n d
lrp were constantly expressed in the untreated SK-MEL-3
tumor, whereas mrp2-mRNA could not be detected in any
of the untreated tumor samples. This pattern of expression
was neither remarkably inﬂuenced by the application of
hyperthermic temperatures nor by the addition of the
cytostatic drug vinblastine, nor did variation of the length
of perfusion appreciably change expression of the studied
chemoresistance genes. In single-tumor samples, a tempo-
rarysuppressionofmrp1ingroupsI,II,andIIIwasobserved
as well as a passing induction of mrp2 in groups II, III, and
IV. No later than 5 hours after the 60-minute perfusion time,
the original pattern of expression was restituted as detected
in the untreated tumor. Detection of the p-glycoprotein by
western blot analysis corresponded to the results of mdr1
expression by RT-PCR (data not shown). Variability in
expression of single genes within the subgroups at diﬀerent
times was low: there was a congruence of expression in 51 of
60 subgroups (85%). Deviations within a group at a deﬁned
time could correspond to a true therapeutic eﬀect, but could
also be caused by the immanent variability of measurements
in biological systems. A fundamental change of the intrinsic
“resistance pattern” following HILP could not be observed in
the SK-MEL-3 tumor.
3.2. Expression of Heat Shock Protein 72. The SK-MEL-3
tumor constitutively expressed HSP72. At normothermic
tissue temperatures (group I), only a temporary 1.5-fold
induction in comparison with the base line of the untreatedJournal of Oncology 5
tumor was observed after 30 minutes. The administration
of vinblastine under normothermic conditions (group II)
was associated with an approximately 2.5-fold increase of
HSP72 production, which dropped to a 1.5-fold rate of
expression after 90 minutes. 5 hours postoperatively (60-
minute perfusion time), the level of the untreated tumor was
reached again.Hyperthermia alone caused adelayed increase
of HSP72 expression by factor 1.5, which was kept even
for 5 hours after the perfusion had been terminated (group
III). Against the expectations, only a 1.5-fold induction was
measured in combined application of hyperthermia and
vinblastine (group IV), though it was observed after only 30
minutes of perfusion and persisted as long as 5 hours after
the perfusion had been terminated.
4. Discussion
Chemoresistance of malignant melanoma is a well-known
phenomenon. Even with the most eﬀective cytostatic drug,
that is, dacarbazine, remissions are reported to be only as
highas14–33%inthemetastasizedstageofdisease[14].One
of the best-characterized mechanisms of chemoresistance
is the mdr1 gene, but some studies have shown that it is
rarely overexpressed in malignant melanoma [15–18]. On
the other hand, increased expression of the chemoresistance-
associated transport proteins MRP and LRP was found in
melanoma cell lines as well as in primary and metastatic
melanoma that could explain resistance towards lipophilic,
natural compounds, but not towards alkylating agents [16].
The SK-MEL-3 tumor constitutively expressed mdr1,
mrp1, and lrp. Because coexpression of several mechanisms
of resistance is related to prognosis [18–20], the SK-MEL-3
tumor can be considered as a relatively resistant variant with
an unfavourable susceptibility. This is supported by the fact
that the tumor was isolated from a lymph node metastasis
from a patient that had been pretreated with Methyl-
CCNU. Cytostatic pretreatment can also be correlated with
the presence of mdr1-mRNA and p-gp in the SK-MEL-
3 tumor because the incidence of mdr1 expression has
been observed to increase following previous chemotherapy,
for example, in acute myeloic leucemia, plasmocytoma, or
osteosarcoma, and adversely inﬂuences adversely remission
rate and prognosis of relapsed tumors [21]. In contrast,
Schadendorf et al. [17] did not ﬁnd an enhanced induction
of p-gp in vindesine- and cisplatin-pretreated metastasic
melanoma.
The pattern of expression of chemoresistance genes was
not changed by hyperthermic isolated limb perfusion and
seems irreversibly determined. Despite high concentrations
of the cytostatic drug and the exposition towards hyperther-
mictemperatures,onlytemporaryeﬀectsongeneexpression,
that is, mrp1 (suppression) and mrp2 (induction) could be
observed. These were limited to the action of treatment.
Apparently, even high-dose thermochemotherapy is not able
to alter transcriptional activity of chemoresistance genes.
Although the results may only apply to the SK-MEL-3
tumor and the number of study animals in each subgroup
was rather small to draw a ﬁnal conclusion, preliminary
results in melanoma patients treated by HILP underline this
observation [22].
Should this be conﬁrmed in further experimental and
clinical studies, it would be desirable to deﬁne the resistance
pattern preoperatively for better evaluation of the response
to HILP or adjusting the drug regimen more individually to
each patient, that is, a calculated choice of agents according
to the individual resistance pattern. Furthermore, an addi-
tional administration of blocking agents for inhibition of
resistance genes, that is, inhibition of mdr1 by verapamil-
or ciclosporine-derivatives can be imagined. There are ﬁrst
promising clinical experiences with such modulators of
chemoresistance in the systemic treatment of refractory non-
Hodgkin lymphoma and plasmocytoma [23, 24], but side
eﬀects of the therapy were limiting. The regional action of
HILP should oﬀer an ideal indication for these substances
because systemic side eﬀects of the therapy are negligible.
In the literature, increased expression of HSP (HSP27,
HSP70) plays an important role in reduced sensitivity
towards cytostatic drugs [25–27]. A direct correlation of
chemoresistance and heat shock has been postulated by
Chin et al. [28, 29] and Kioka et al. [30] who observed an
ampliﬁcation of mdr1-mRNA together with an enhanced
resistance of tumor cells in vitro towards vinblastine after
heat exposure. The explanation that was given for this
result was the presence of heat shock-responsible consensus
elements in the mdr1-promotor region. In melanoma cells
not only a chemically and heat-induced expression of
HSP (HSP72) has been demonstrated [31–34], but also a
constitutive overexpression that was independent of stress
(HSP27, HSP72, HSP90), as was the case in the SK-MEL-3
tumor. Again, constitutive expression of HSP was associated
with an advanced tumor stage and ampliﬁed resistance
towards thermal and cytostatic drug damage [35–37].
The cellular response to stress, that is, the increase in
transscriptional activity of HSP, takes place within minutes
[38]. In vitro studies in melanoma cells showed the level of
HSP expression to be dependent on time and temperature,
with the maximal rate of synthesis at 42
◦Ca n d9h o u r s
exposure reaching a steady state with levels not much higher
than constitutive expression following continued exposure
[31].
These in vitro results were also obvious in the in
vivo tumor model which was presented. The sensitive
stress reaction is recognized by the fact that even opera-
tive manipulation alone (normothermic perfusion without
vinblastine) was associated with a raised HSP synthesis,
probably due to limb ischemia during the clamping of the
vessels for cannulation. The administration of vinblastine in
normothermic perfusions resulted in peak values of HSP72
synthesis after 30 minutes (factor 2.5), which dropped to
the base line of the untreated tumor not later than 5 hours
after 60-minute perfusion, maybe as a consequence of mdr1-
mediated drug eﬄux of vinblastine. The increase of HSP72
expression in the tumor tissue during hyperthermic temper-
atures was clearly evident, but with a delayed maximum for
hyperthermia alone (60 minutes) in comparison with the
combination of hyperthermia and vinblastine (30 minutes).
Hyperthermic temperatures led to a persistently enhanced6 Journal of Oncology
synthesis of HSP72 in comparison with normothermia.
This continued for hours after the operation. The reason
why the combination of both stress factors (cytostatic drug
and hyperthermia) had a smaller eﬀect on the level of
HSP72expressionremainsunclear,butatemporaryparalysis
of cell function including protein synthesis with gradual
recovery could be discussed. The changes in the rate of
synthesis by a factor of 1.5 to 2.5 may be less impressive
than in an in vitro setting, but the vascularized structure
of a solid tumor undoubtedly represents a more complex
system so that despite standardized experimental conditions,
biologic eﬀects are more diﬃcult to assess. The constitutive
expression of HSP72 in SK-Mel-3 tumor may add to this
observation.
5. Conclusion
As has been reported earlier [1, 39, 40], the proposed exper-
imental model, that is, performance of miniaturised limb
perfusion in nude rats with implanted melanoma xenografts
simulating the clinical setting proved to be suitable for
the investigation of the question of how well-characterized
mechanisms of resistance are directly inﬂuenced by HILP.
On the one hand, the inherent, irreversible pattern of
chemoresistance genes and the induction of HSP in the
tumor itself during treatment oﬀer a possible explanation
for a primary (no or partial response) or secondary failure
(early local recurrence) of HILP. On the other hand, there is
clinical evidence that apart from a resistant cell phenotype
there are additional factors such as tumor burden, which are
important for response or resistance of the tumor towards
therapy [22].
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